Fluorometholone acetate: clinical evaluation in the treatment of external ocular inflammation.
Separate, randomized, double-masked clinical studies were conducted to determine the therapeutic efficacy of fluorometholone acetate, a new ophthalmic corticosteroid formulation, in suppressing external ocular inflammation (conjunctivitis, episcleritis, scleritis). Fluorometholone acetate 0.1% was compared to fluorometholone 0.1%, and the acetate formulation was found to be significantly (p = 0.03) more effective. Fluorometholone acetate 0.1% also was compared to prednisolone acetate 1.0%; there was no significant difference (p = 0.49) between these two corticosteroids in their ability to suppress external ocular inflammation. It appears that alteration of fluorometholone from its alcohol base to its acetate derivative changes the drug from a moderately effective to a highly effective anti-inflammatory agent.
D000328:Adult; D002986:Clinical Trials as Topic; D003231:Conjunctivitis / Q000188:drug therapy; D004311:Double-Blind Method; D005128:Eye Diseases / Q000188:drug therapy*; D005260:Female; D005469:Fluorometholone / Q000627:therapeutic use; D006801:Humans; D007249:Inflammation / Q000188:drug therapy; D008297:Male; D011239:Prednisolone / Q000031:analogs & derivatives / Q000627:therapeutic use; D011897:Random Allocation
C009935:prednisolone acetate; D011239:Prednisolone; D005469:Fluorometholone